| Industry | Regenerative medicine |
|---|---|
| Founded | February 16, 2016 |
| Headquarters | , |
Key people | Bob Maguire (CEO), Phillip Larson (President) |
| Owner | Alan Sherman, DPM and Michael Shore, DPM |
| Website | www |
Axolotl Biologix, Inc. (AxoBio) is an American regenerative medicine company focused on improving the quality of life for people around the world.[1]
Axolotl Biologix was founded on February 16, 2016 with its headquarters located in Phoenix, Arizona and an additional research lab and manufacturing facility located at NACET (Northern Arizona Center for Entrepreneurship and Technology) in Flagstaff, Arizona.
In March 2017, AxoBio acquired Protein Genomics’ Research Lab and also signed an exclusive worldwide license agreement with Protein Genomics. The license agreement allows AxoBio to use Protein Genomics’ patents and manufacturing knowledge for a biomimetic skin substitute made from biomaterial called Tropoelastin, which is referred to as Elastropin.[2] AxoBio has an exclusive worldwide license to the patents for Tropoelastin, the precursor to elastin and is the only company in the world that can use Tropoelastin in medical applications.[2] Elastin is present throughout the human body and is critical to provide elasticity and tensile strength for organs in our bodies. Some of these organs include the skin, the heart, the bladder, muscles, along with many other structures in the body.[3]
In October 2017, Axolotl Biologix, was awarded a $224,500 grant funded by the National Institutes of Health (NIH) for the research and development of a wound-healing device for chronic wounds in patients suffering from diabetic foot ulcers.[4]
Axolotl Biologix offers optimization of regenerative medicine through research, science and evidence-based clinical applications to improve the quality of life for people around the world through better and affordable solutions in orthopedics, sport injuries, wound care, cardiovascular, ophthalmic, diabetes, and other areas.[5]
AxoBio currently markets three products that are derived from the human amnion. The first two products are an amnion-derived fluid called AxoBioFluid®, which is available in an ambient (room temperature version) along with a cryopreserved (-40c to -80c) version. The third product is AxoBioMembrane™, which is created from the lining of the placenta. This is used for wound care and surgical applications[6] The company's next generation of products include an extracellular matrix using Tropoelastin to create a skin substitute with elasticity and tensile strength. Other products on its product roadmap using Tropoelastin include a surgical mesh, a cardiac patch, and a biocompatible blood vessel.[7]
((cite news)): Italic or bold markup not allowed in: |publisher= (help)
((cite news)): Italic or bold markup not allowed in: |publisher= (help)
((cite news)): Italic or bold markup not allowed in: |publisher= (help)
((cite news)): Italic or bold markup not allowed in: |publisher= (help)
((cite news)): Italic or bold markup not allowed in: |publisher= (help)
((cite news)): Italic or bold markup not allowed in: |publisher= (help)
((cite news)): Italic or bold markup not allowed in: |publisher= (help)
((cite news)): Italic or bold markup not allowed in: |publisher= (help)